Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open-Label Study to Evaluate the Effect of Renal Impairment and Dialysis Treatment on the Pharmacokinetics of a Single 3 mg Cytisinicline Dose.

NCT05631938 is registered in ClinicalTrials.gov with Achieve Life Sciences as lead sponsor.

NCT NCT05631938
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05631938 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open-Label Study to Evaluate the Effect of Renal Impairment and Dialysis Treatment on the Pharmacokinetics of a Single 3 mg Cytisinicline Dose.
Lead sponsor
Achieve Life Sciences
Phase
Phase 1
Overall status
Completed
Start date
January 10, 2023
Completion date
September 4, 2023
Enrollment
44 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

renal impairment